Given that PDL1 expression in B16F10 cells (Figure S2) and PD1 expression in CD8+ T cells (Figures S3 and S4) and that IL-12 activates a local immune response in the primary melanoma via the recruitment of T lymphocytes to the tumor site as well as triggering the exposure and recognition of tumor antigens, it may be possible to enhance the antitumor effect by combining pIL-12 GET with checkpoint inhibitors. Here, CD8A is linked to neoplasm.